Other Voices
After last week's surprise resignation of Food and Drug Administration Commissioner Lester Crawford, President Bush needs to find a highly qualified, apolitical successor who devotes full attention to the agency.
Crawford was confirmed in July after 16 months as acting FDA chief. His brief tenure was marred by controversy over the safety of Vioxx and similar painkillers, lax regulation of medical devices, and a delay in whether to approve the Plan B emergency contraceptive for sale over the counter.
An FDA advisory panel recommended approval for Plan B in 2003. Amid strong opposition from anti-abortion groups, Crawford put off a decision. Last month a top FDA official resigned over the delay, complaining that scientific evidence had been overruled.
Meanwhile, Republican Sen. Charles Grassley of Iowa said the FDA under Crawford's leadership was too cozy with the pharmaceutical industry and more likely to hide than disclose information to the public. Yet the agency is charged, according to its mission statement, with providing the public "accurate, science-based information" on food and medicine.
Bush has named National Cancer Institute Director Andrew von Eschenbach to be acting FDA commissioner. Eschenbach has said he intends to hold both jobs.
In an age of breakthroughs in drugs and medical technology and possible threats to the nation's food supply, FDA commissioner is too critical a position for a part-timer. Bush needs to find a full-time, permanent chief - soon.
